24×7 Emergency Care

1-8-31/1, Minister Road, Secunderabad, Telangana 500003

EMERGENCY:For urgent neurosurgical assessment — sudden neurological deterioration, severe headache, seizure, or DBS device malfunction —call040-46324365immediately — 24 hours, 7 days— 24/7

FUNCTIONAL NEUROSURGERY · DEEP BRAIN STIMULATION

Deep Brain Stimulation (DBS) in Hyderabad — Parkinson's Disease and Movement Disorders at KIMS

STN, GPi, and Vim DBS for Parkinson's disease, essential tremor, and dystonia — asleep DBS with O-Arm, ongoing programming support, and MRgFUS as a non-surgical alternative, at KIMS Neuroscience, Secunderabad, Hyderabad.

View Our Specialists

About This Page

Years of Restored Function in Diseases That Cannot Be Cured

Deep brain stimulation is the most transformative surgical treatment in the history of movement disorder neurology. When a patient with advanced Parkinson's disease — who has spent years cycling between the rigid, frozen “off” state and the writhing, uncontrollable “on” state of levodopa-induced dyskinesia — has DBS electrodes activated in the subthalamic nucleus, the improvement is often immediate and dramatic: the freezing stops, the dyskinesia disappears, the body moves freely again. The DBS does not cure Parkinson's disease. The neurodegeneration continues. But it restores years of functional independence and quality of life that the disease had taken away.

KIMS Hyderabad performs DBS for Parkinson's disease, essential tremor, and dystonia, and is one of the most experienced DBS centres in South India. The DBS programme at KIMS is delivered by an experienced functional neurosurgery team trained at premier neurosurgical institutions, and operates in close collaboration with the KIMS Movement Disorders Centre.

What DBS does — without destroying tissue: DBS implants thin electrodes into specific brain targets and delivers continuous high-frequency electrical stimulation that modulates the abnormal neural circuit activity causing motor symptoms — without destroying tissue. The stimulation can be adjusted, turned on or off, and reprogrammed at any time after implantation. Unlike ablative procedures (where the target is permanently destroyed), DBS is adjustable and reversible — stimulation parameters can be changed as the disease progresses or if side effects occur.
The subthalamic nucleus — the PD target: In Parkinson's disease, the substantia nigra loses its dopaminergic neurons, disrupting basal ganglia motor circuit regulation. The subthalamic nucleus (STN) — a small almond-shaped structure approximately 5×3×5 mm in the diencephalon — becomes pathologically overactive, firing excessively in a synchronised, oscillatory pattern that produces the cardinal PD motor features: bradykinesia, rigidity, and tremor. DBS electrodes placed in the STN deliver 130–185 Hz stimulation that suppresses this pathological oscillation. The analogy: the STN in PD is like a stuck car horn — the DBS is a hand pressed on the horn to silence the abnormal noise. The car (the motor system) then runs normally again. STN DBS allows 30–50% levodopa dose reduction, which reduces levodopa-induced dyskinesia.
Three targets and their specific indications: STN: primary PD target · improves all cardinal PD features (bradykinesia, rigidity, tremor) · allows 30–50% levodopa dose reduction · most widely used DBS target globally. GPi: alternative PD target · better for patients with prominent dyskinesia (GPi DBS does not require levodopa reduction to work, unlike STN) · preferred when pre-existing cognitive impairment makes the cognitive side-effect risk of STN DBS unacceptable · primary target for generalised dystonia, especially DYT1/TOR1A primary dystonia where 60–80% improvement is achieved. Vim thalamus: tremor target · >80% tremor reduction for essential tremor and tremor-dominant PD · largely replaced by MRgFUS for unilateral tremor in eligible patients (SDR ≥0.4) · remains standard for bilateral tremor or patients with SDR <0.4 (who cannot have MRgFUS).
MRgFUS vs DBS for tremor — how the choice is made at KIMS: Both MRgFUS and DBS are available at KIMS for tremor — and the initial movement disorders consultation discusses both options for every eligible patient. MRgFUS: no surgery, no implant, no anaesthesia · unilateral only (cannot treat both hands) · non-adjustable (the thermal lesion is permanent) · requires SDR ≥0.4 (approximately 20–30% of patients excluded) · same-day procedure · first in Telangana/AP at KIMS. DBS Vim: surgical implant required · adjustable and reversible · bilateral treatment possible · no SDR limitation · battery replacement every 5–7 years (non-rechargeable IPG) or 15–20 years (rechargeable IPG). The choice depends on: unilateral vs bilateral tremor; patient's SDR; preference for implant-free vs adjustable; fitness for surgery.
Asleep DBS with O-Arm — what it means: Traditional DBS is performed with the patient awake during electrode implantation to allow microelectrode recording (MER) — neurophysiological recording of the characteristic firing pattern of the target nucleus confirms accurate electrode placement. Asleep DBS uses intraoperative CT (O-Arm) to confirm electrode position by imaging, without requiring the patient to be awake during the procedure. Advantages: more comfortable for the patient; allows general anaesthesia for the entire procedure; avoids the physiological changes (increased tremor, anxiety) that can occur during awake surgery. At KIMS, both awake (with MER) and asleep (with O-Arm) DBS approaches are available.
Programming — the post-surgical service that matters: DBS is not a one-time procedure — it requires ongoing programming to optimise the stimulation parameters (pulse width, frequency, amplitude, electrode contact configuration) as the disease evolves and the patient's response changes over years. The initial programming takes place 2–4 weeks after surgery; parameters are then adjusted over the following months. The KIMS DBS programme includes structured post-operative programming visits and ongoing support from the movement disorders team. Battery replacement: non-rechargeable DBS batteries typically last 5–7 years depending on the stimulation parameters used; rechargeable DBS systems (available for new implants) extend battery life to 15–20 years.

Book a Consultation

Speak directly with the movement disorders and DBS team. No referral required. Monday to Saturday.

040-44885000Email: neuroscience@kimshospitals.com

★ Definition — Deep Brain Stimulation (DBS)

What DBS Is — Why It Restores Function Without Destroying Tissue

Deep brain stimulation is a surgical treatment in which thin electrodes are implanted into specific targets within the brain and connected via extension wires under the skin to a pulse generator (neurostimulator) implanted beneath the clavicle. The pulse generator delivers continuous high-frequency electrical stimulation to the brain target, modulating the abnormal neural circuit activity that causes motor symptoms in Parkinson's disease, essential tremor, and dystonia — without destroying brain tissue. The stimulation can be adjusted, turned on or off, and reprogrammed at any time after implantation.

The Three DBS Targets & One Non-Invasive Alternative

The DBS Treatment Stack at KIMS

Three brain targets — each chosen according to the condition and the dominant symptom — and a non-invasive focused-ultrasound alternative for eligible tremor patients. Every candidate is assessed jointly with the KIMS Movement Disorders Centre.

Primary PD Target

Target 1: Subthalamic Nucleus (STN)

A 5 × 3 × 5 mm almond-shaped diencephalic structure that is pathologically overactive in Parkinson's disease. 130–185 Hz stimulation suppresses the synchronised oscillation that drives bradykinesia, rigidity, and tremor — improves all cardinal PD features and enables 30–50% levodopa dose reduction.

Dystonia & PD Alternative

Target 2: Globus Pallidus Interna (GPi)

Alternative PD target — better for patients with prominent dyskinesia or pre-existing cognitive impairment (lower cognitive side-effect risk than STN). The preferred target for generalised and segmental dystonia, particularly DYT1/TOR1A primary dystonia where 60–80% improvement is achieved.

Tremor Target

Target 3: Vim Thalamus

Ventral intermediate nucleus of the thalamus — the primary target for essential tremor and tremor-dominant PD. >80% tremor reduction. Largely replaced by MRgFUS for unilateral tremor in eligible patients, but remains standard for bilateral tremor or patients with skull density ratio <0.4.

Non-Invasive Tremor Option

Alternative: MRgFUS Vim Thalamotomy

Completely non-invasive focused ultrasound option for unilateral tremor — no incision, no implant, no anaesthesia. 75% tremor reduction at 12 months (NEJM 2016). Requires skull density ratio ≥0.4. Available at KIMS — discussed alongside DBS at the initial movement disorders consultation.

Section 1

How DBS Works — Targets, Mechanism, and Why It Beats More Medication

The subthalamic nucleus — the PD target

In Parkinson's disease, the loss of dopaminergic neurons in the substantia nigra disrupts the basal ganglia circuit that normally regulates the smooth initiation and execution of voluntary movement. The subthalamic nucleus (STN) — a small almond-shaped structure in the diencephalon, approximately 5 × 3 × 5 mm — becomes pathologically overactive in PD, firing excessively in a synchronised, oscillatory pattern that propagates through the motor circuit and produces the cardinal motor features of PD: bradykinesia (slowness), rigidity, and tremor. DBS electrodes placed in the STN deliver continuous high-frequency stimulation (130–185 Hz) that suppresses this pathological oscillation, restoring more normal motor circuit function. The analogy: the STN in PD is like a stuck car horn — the DBS is a hand pressed on the horn to silence the abnormal noise. The car (the motor system) then runs normally again.

The three DBS targets and their indications

(1) Subthalamic nucleus (STN): the primary target for Parkinson's disease · Improves all cardinal PD motor features · Allows significant levodopa dose reduction (30–50%) · The most widely used DBS target globally. (2) Globus pallidus interna (GPi): alternative PD target · Better for PD patients with prominent dyskinesia · Preferred target for dystonia (generalised and segmental) · Does not allow as much levodopa reduction as STN · Better for PD patients with cognitive impairment (less cognitive side effect risk than STN). (3) Ventral intermediate nucleus of the thalamus (Vim): the primary target for essential tremor and tremor-dominant PD · Very effective for tremor suppression (>80% tremor reduction) · Does not improve other PD features (bradykinesia, rigidity) · Largely replaced by MRgFUS for unilateral tremor in appropriate patients, but remains standard for bilateral tremor or patients with low SDR for MRgFUS.

Why DBS works better than increasing medication

In advanced PD, the response to levodopa becomes increasingly problematic: (1) Wearing-off: levodopa effect lasts shorter and shorter — the patient oscillates between good “on” states (mobile, sometimes with dyskinesia) and bad “off” states (frozen, rigid, tremoring). (2) Dyskinesia: involuntary writhing movements from peaks of levodopa effect. (3) Medication complexity: 5–8 doses of levodopa per day, plus dopamine agonists, MAO-B inhibitors, COMT inhibitors — each with its own side effects. DBS bypasses this pharmacological complexity by providing continuous, stable neuromodulation that is not dependent on the variable gastric absorption and plasma level of levodopa. The motor state becomes smoother and more predictable. Levodopa can often be reduced significantly, decreasing dyskinesia and side effects while maintaining motor benefit.

Section 2

Patient Selection — Who Benefits Most

The ideal DBS candidate for Parkinson's disease

Robust levodopa response: DBS produces benefit roughly equivalent to the best response to levodopa — patients with excellent levodopa response have excellent DBS outcomes; patients with minimal levodopa response have minimal DBS benefit · Motor fluctuations: wearing-off and dyskinesia are the primary indications · Adequate duration of disease: typically ≥4–5 years (to confirm diagnosis and allow medication optimisation) · Age typically <70–75 (though older patients can benefit from GPi DBS, which has lower cognitive risk) · No or mild cognitive impairment · No severe psychiatric illness (severe depression, psychosis) · Treatable or controlled psychiatric comorbidity · Realistic expectations (DBS is not a cure and does not stop disease progression).

Who does NOT benefit from DBS for Parkinson's disease

DBS is unlikely to help if: Levodopa does not significantly improve the PD symptoms: DBS targets the same motor circuits as levodopa · Features that do not respond to levodopa — postural instability, freezing of gait, dysarthria, cognitive symptoms — do not respond to DBS either · Significant dementia: DBS can worsen cognitive function in patients with pre-existing moderate–severe cognitive impairment · Atypical parkinsonism (MSA, PSP, CBD): the pathology in these conditions is not STN overactivity and DBS is not effective · Active systemic infection or coagulopathy.

Conditions, Targets, and Evidence

Which DBS Target for Which Condition

The comparison matrix below summarises the conditions for which DBS is offered at KIMS, the brain target used for each, the primary clinical benefit, and the strength of supporting evidence.

Condition

DBS Target

Primary Benefit

Evidence Level

Parkinson's disease — motor fluctuations

STN or GPi

50–70% reduction in off-time · 50–60% dyskinesia reduction

Class I — multiple RCTs

Essential tremor

Vim thalamus

>80% tremor reduction · Bilateral possible

Class II–III · compare with MRgFUS for unilateral

Tremor-dominant PD

Vim or STN

>75% tremor suppression

Class II

Generalised dystonia

GPi

50–70% reduction in dystonia score at 1 year

Class I (for primary dystonia)

Segmental dystonia (cervical)

GPi

50–60% improvement

Class II

DYT1 dystonia (TOR1A gene)

GPi

60–80% improvement — best DBS response for dystonia

Class II

OCD (refractory)

Anterior limb IC / NAcc

≥35% improvement in Y-BOCS

Class II — humanitarian exemption FDA

Section 3

The DBS Procedure at KIMS — Step by Step

From pre-operative assessment through electrode implantation, pulse generator placement, programming, and long-term battery management — the full DBS pathway at KIMS proceeds in five discrete stages.

Pre-operative assessment

Full neurological evaluation by the movement disorders team · Levodopa challenge test (motor examination in “off” state after overnight medication hold, then 90 minutes after supramaximal levodopa dose — the UPDRS-III on/off scores predict DBS outcome) · Neuropsychological assessment · Psychiatric evaluation · MRI brain (target planning + exclusion of white matter disease or atrophy) · Pre-operative discussion of realistic expectations, risks, and post-operative programming commitment.

Electrode implantation

Performed under general anaesthesia at KIMS (asleep DBS surgery): the historical standard was awake DBS surgery with microelectrode recording (MER) to confirm electrode position by neural signals. Modern centres increasingly use imaging-guided asleep DBS with intraoperative CT or O-Arm confirmation — which achieves equivalent targeting accuracy without the discomfort and anxiety of the awake procedure. At KIMS, high-resolution pre-operative MRI targeting identifies the STN, GPi, or Vim target · The electrode is implanted via a stereotactic burr hole and advanced to the target · O-Arm intraoperative imaging confirms electrode position before the extension wire and pulse generator are implanted in the same session.

Pulse generator implantation

The DBS pulse generator (IPG — implantable pulse generator) is placed beneath the skin below the clavicle, under general anaesthesia in the same session as the electrode implantation. The extension wire runs subcutaneously from the IPG behind the ear and into the cranium where it connects to the electrode. The procedure takes 3–5 hours for bilateral DBS implantation. Hospital stay: 3–5 days.

DBS programming — the art of DBS

Programming is the process of adjusting the stimulation parameters (which contact of the electrode is active, the amplitude in volts, the pulse width in microseconds, and the frequency in Hz) to achieve the optimal balance of motor benefit and side effect minimisation. Programming begins 2–4 weeks after surgery (to allow post-operative oedema to settle and the electrode to stabilise). Multiple programming sessions over the first 3–6 months are required to optimise the settings. The movement disorders team at KIMS provides ongoing programming support. Modern IPGs can be adjusted wirelessly (the programmer holds a device near the IPG) and some allow patient-controlled adjustments within a set range.

Battery replacement

Non-rechargeable IPGs typically last 5–7 years (shorter with high stimulation requirements) and must be replaced under general anaesthesia in the interventional suite — a 30-minute procedure. Rechargeable IPGs last 15–20 years (charged externally through the skin) — eliminating most battery replacement surgeries. At KIMS, the choice between rechargeable and non-rechargeable is discussed with the patient based on age, compliance, and technical preference.

Section 4

DBS vs MRgFUS for Tremor — The Choice at KIMS

For patients with essential tremor or tremor-dominant Parkinson's disease, both DBS and MRgFUS are effective options. The KIMS movement disorders team discusses both at the initial consultation for eligible patients.

Feature

DBS (Vim Target)

MRgFUS (Vim Thalamotomy)

Surgery required

Yes — craniotomy, implant, chest incision

No — completely non-invasive

General anaesthesia

Yes

Not required

Bilateral treatment

Yes — standard for bilateral tremor

Not recommended (risk dysarthria)

Reversibility

Yes — adjustable and reversible

No — permanent lesion

Tremor reduction

>80% in most patients

75% at 12 months (NEJM 2016)

Battery replacement

Every 5–7 years (non-rechargeable IPG) · 15–20 years (rechargeable IPG)

None — no device

Skull density ratio

No requirement

SDR ≥0.4 required

Best for

Bilateral tremor · PD with multiple motor features · Need for adjustability

Unilateral tremor · Surgery-averse · Elderly · High anaesthetic risk

Key Clinical Facts

What the Evidence Shows

DBS at KIMS is grounded in published evidence, operative experience, and ongoing programming support from the KIMS Movement Disorders Centre. The following points summarise the clinically significant facts every patient and family should know.

KIMS Hyderabad is one of the most experienced DBS centres in South India

DBS programme delivered by an experienced functional neurosurgery team trained at premier neurosurgical institutions, with 30+ years of movement disorder surgery experience

STN DBS achieves 50–70% reduction in off-time and 50–60% dyskinesia reduction in advanced Parkinson's disease (Class I evidence)

Asleep DBS with O-Arm intraoperative imaging is performed at KIMS — equivalent targeting accuracy to traditional awake MER surgery without the discomfort and anxiety

GPi DBS for DYT1/TOR1A primary generalised dystonia achieves 60–80% improvement — the best DBS response for dystonia

Levodopa challenge test on/off UPDRS-III scores predict DBS outcome — a >30% improvement is a strong positive predictor

Dystonia DBS benefit develops gradually over 3–12 months — patients and families must commit to this timeline (unlike PD where benefit appears within hours to days of activation)

Rechargeable IPGs last 15–20 years versus 5–7 years for non-rechargeable IPGs — the choice is discussed at KIMS based on age, compliance, and technical preference

Fact	Details
What DBS achieves	Modulates abnormal motor circuits without destroying tissue · Adjustable, reversible · STN DBS: all PD cardinal features improved + 30–50% levodopa reduction · GPi DBS: primary dystonia 60–80% improvement
3 targets	STN: PD (primary target, all cardinal features) · GPi: PD (dyskinesia-dominant, cognitive impairment) + dystonia (DYT1/TOR1A) · Vim: tremor (>80% reduction, bilateral or SDR <0.4)
MRgFUS alternative	Non-surgical Vim thalamotomy for unilateral tremor · No incision, no implant, no anaesthesia · 75% tremor reduction at 12m · Requires SDR ≥0.4 · Discussed alongside DBS at initial consultation at KIMS
Asleep DBS	O-Arm intraoperative CT for electrode position confirmation · No awake microelectrode recording required · Full general anaesthesia · Available at KIMS alongside traditional awake DBS
DBS device malfunction	Sudden neurological deterioration or stimulator failure: emergency · Call 040-46324365 immediately · The KIMS DBS team provides 24/7 emergency DBS support
Programming	Post-operative programming visits at 2–4 weeks, then ongoing · Parameters adjusted as disease evolves · Battery: 5–7 years non-rechargeable IPG; 15–20 years rechargeable IPG
Contact	040-44885000 (movement disorders + DBS outpatient) · 040-46324365 (24×7 emergency) · neuroscience@kimshospitals.com

Related Treatments

Explore related functional neurosurgery and movement disorder procedures at KIMS Neuroscience:

Functional Neurosurgery MRgFUS Focused Ultrasound Epilepsy Surgery Neuronavigation

Common Questions

Frequently Asked Questions

The scenario you describe — good medication response followed by wearing-off and motor freezing — is one of the clearest indications for DBS in Parkinson's disease. Levodopa wearing-off is the primary indication for DBS consideration, and your father's 8-year disease duration with clear medication response is consistent with a good DBS candidate profile. What DBS would likely achieve in this situation: (1) Extension of the “on” time: DBS provides continuous stimulation that smooths out the on/off fluctuations, reducing the period of wearing-off and extending the effective motor state. (2) Reduction of levodopa dose: most STN DBS patients reduce their levodopa dose by 30–50%, which secondarily reduces dyskinesia (if that is also present). (3) Improvement in “off” state function: the “frozen” state is significantly improved by STN DBS. The pre-operative assessment at KIMS begins with a levodopa challenge test: your father's UPDRS motor score is measured in the “off” state (after overnight medication hold) and in the “on” state (90 minutes after a supramaximal levodopa dose). The percentage improvement (on/off ratio) predicts the DBS response. A >30% improvement in the levodopa challenge test is a strong positive predictor. Call 040-44885000.

Gradual reduction in DBS benefit over time has several possible causes: (1) Disease progression: Parkinson's disease continues to advance after DBS implantation. The features that did not respond to levodopa (and therefore did not respond to DBS) — postural instability, falls, cognitive symptoms, dysphagia — will worsen with disease progression regardless of DBS. DBS does not slow the underlying neurodegeneration. (2) Tolerance: in some patients, the stimulation amplitude needs gradual upward adjustment as the disease progresses to maintain motor benefit. (3) Electrode migration or lead fracture: rarely, the DBS electrode can shift from its original position or the extension wire can develop a fracture — causing sudden loss of benefit. A lead X-ray or fluoroscopy confirms wire integrity. (4) Battery depletion: if a non-rechargeable IPG was used, the battery may be depleting · The device can be checked with the programmer. (5) Suboptimal programming: programming can almost always be improved when benefit is waning. At KIMS, a programming review session should be the first step — before any surgical intervention. Call 040-44885000.

If you want to avoid surgery, MRgFUS is the treatment to investigate first — provided you meet the eligibility criteria. MRgFUS is completely non-invasive: no incision, no anaesthesia, no implant, no battery. The tremor reduction achieved by MRgFUS (approximately 75% at 12 months in the NEJM 2016 trial) is equivalent to Vim DBS for unilateral tremor. The critical eligibility requirement for MRgFUS is the skull density ratio (SDR) ≥0.4 — measured from a head CT. Approximately 20–30% of patients have an SDR below this threshold and cannot have MRgFUS. For these patients, Vim DBS is the appropriate alternative. Other factors favouring DBS over MRgFUS: if both hands are significantly affected (DBS can be bilateral; MRgFUS cannot) · If the tremor is from Parkinson's disease and other PD features (rigidity, bradykinesia) also need treatment (STN DBS addresses multiple PD features; MRgFUS addresses only tremor) · If you want a reversible treatment (DBS can be reprogrammed or turned off; MRgFUS cannot). At KIMS, both MRgFUS (first in Telangana/AP) and DBS are available, and the movement disorders team discusses both at the same consultation for eligible patients. Call 040-44885000.

Yes — deep brain stimulation of the globus pallidus interna (GPi) is the most effective treatment available for generalised primary dystonia and produces dramatic and durable improvement in a high proportion of patients. For primary generalised dystonia (particularly DYT1/TOR1A-associated dystonia), GPi DBS achieves 60–80% reduction in dystonia severity scores at 1–3 years — often transforming a person who could barely walk from severe limb and trunk twisting to near-normal function. Important points about dystonia DBS: (1) The response is slow: unlike PD where DBS benefit is seen within hours to days of activation, dystonia DBS benefit develops gradually over 3–12 months. The family must understand and commit to this timeline. (2) Primary dystonia (no structural brain pathology) responds much better than secondary dystonia (dystonia from brain injury, cerebral palsy, or other structural causes). The DYT1/TOR1A gene mutation is the strongest predictor of a very good DBS response. (3) Age is not a barrier: GPi DBS has been performed successfully in children as young as 5–7 years with generalised dystonia. At KIMS, the DBS programme evaluates dystonia patients in collaboration with the movement disorders neurology team. A genetic test for TOR1A and other dystonia genes is performed as part of the evaluation. Call 040-44885000.

Years of On/Off Fluctuations. Tremor That Has Made Ordinary Life Impossible. Dystonia Stealing the Future. — DBS at KIMS Hyderabad.

The years of on/off fluctuations that medication can no longer control. The essential tremor that has made ordinary life impossible. The generalised dystonia in a teenager that is stealing the future. DBS at KIMS Hyderabad — movement disorders team, and a programme that starts with an honest assessment of whether DBS is right for your specific situation. Call 040-44885000.

040-44885000

International enquiries: info@kimsneurosciences.com